ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Purchases $89,600.00 in Stock

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster bought 70,000 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was bought at an average cost of $1.28 per share, for a total transaction of $89,600.00. Following the completion of the transaction, the director now directly owns 138,333 shares of the company’s stock, valued at $177,066.24. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

ProMIS Neurosciences Stock Performance

ProMIS Neurosciences stock opened at $1.29 on Friday. The firm has a market capitalization of $24.46 million, a P/E ratio of -1.74 and a beta of 0.62. The company has a 50-day simple moving average of $1.38 and a 200-day simple moving average of $1.71. ProMIS Neurosciences, Inc. has a one year low of $0.95 and a one year high of $3.10.

ProMIS Neurosciences (NASDAQ:PMN) last posted its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. As a group, sell-side analysts forecast that ProMIS Neurosciences, Inc. will post -0.24 earnings per share for the current year.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.